OREANDA-NEWS. According to the results of the first half of 2013 total sales of the top five best selling Rx drugs amounted to RUR 741.79 million, which corresponds to 41.4% of sales in the Rx drugs segment and 31.0% of the Company's total sales.

According to the results of the first half of 2013 the top five best selling Rx drugs are:

• Geptor (Ademetionine; ATC "Digestive tract and metabolism"); sales increased by 45.1% as compared to the same period of the previous year; 16.3% of sales in the Rx drugs segment;

• Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 7.1%;

• Irunine (Itraconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 7.1%;

• Cerepro (Choline Alfoscerate; ATC "Medications for the treatment of the nervous system deseases"); sales in the segment made 5.6%;

• Parclitaxel-LENS (Parclitaxel; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 5.3%;

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.4% of sales.

• Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales in the OTC drugs segment made 40.6%;

• Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 36.7%;

• Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 17.5%;

• Vitasharm and Vitatress (ATC "Vitamins"); sales in the OTC drugs segment made 2.7%;

• Ginkgo biloba (Ginkgo biloba; ATC "Medications for the treatment of urogenital organs"); sales in the OTC drugs segment made 0.9%.

Traditional drugs segment

According to the results of the first half of 2013 the top five best selling prescription medications are:

• Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs for systematic use"); sales in the traditional drugs segment made 38.3%;

• Vero-Ciprofloxacin (Ciprofloxacin; ATC "Antimicrobials for systematic use"); sales in the segment made 17.3%;

• Vero-Loperamide (Loperamide; ATC "Alimentary tract and metabolism"); sales in the segment made 15.2%;

• Pyridoxine (ATC "Alimentary tract and metabolism"); sales in the segment made 14.8%;

• Vero-Flukonazole (Fluconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 8.0%;

Non-pharamaceutical products

According to the results of the first half of 2013 the top five best selling non-pharamaceutical products are:

Conventional antimicrobial adhesive bandages; 44.2% of sales in the segment;

Conventional reel adhesive bandages; 26.7% of sales in the segment;

Therapeutic patches - corn plasters; 12.3% of sales in the segment;

Therapeutic patches - pepper plasters; 9.0% of sales in the segment;

Condoms; 7.2% of sales in the segment.

NEW DRUGS PRODUCTION AND SALES

During the first half of 2013 Veropharm launched production and sales of the following new drugs:

Anfibra (Enoxaparin sodium; ATC "Medications affecting hematogenesis and blood");

Salbutamol (Salbutamol; ATC "Medications for the treatment of respiratory system").

In the first half of 2013 Veropharm has initiated the sales of condoms under its own brand name:

"Sensex" (Condoms; ATC "Medical items").

NEW DRUGS REGISTRATION

During the first half of 2013 Veropharm received registration for the following 2 drugs:

• ACP (Escitolapram, ATC "Medications for the treatment of the nervous system deseases");

Gistamel (Imatinib; ATC " Antineoplastic and immunomodulating agents")

Additionally, 21 more drugs are currently at different stages of the registration process.